oncological management of pancreatic cancer€¦ · oncological management of pancreatic cancer...
TRANSCRIPT
![Page 1: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/1.jpg)
Oncological Management of Pancreatic
Cancer
Pancreatic Cancer UK National Study Day
Yuk Ting MaSenior Clinical Lecturer & Honorary Consultant in
Hepatobiliary Oncology
![Page 2: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/2.jpg)
Outline of talk
• Current treatment
• Adjuvant
• Locally advanced
• Metastatic disease
• Developing areas of work
• Neoadjuvant chemotherapy
• Personalised medicine
• Immunotherapy
![Page 3: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/3.jpg)
Early Locally advanced Metastatic
15% 50%35%
Staging
![Page 4: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/4.jpg)
ADJUVANT CHEMOTHERAPY
![Page 5: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/5.jpg)
Rationale for adjuvant therapy
• 80% will relapse within 1-2 years of surgery
• Disease progression occurs at both local and distant sites
![Page 6: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/6.jpg)
ESPAC1 ESPAC3
Chemo No Chemo HR P value
Median survival 20.1 mths 15.5 mths 0.71
(0.55-0.92)
P=0.09
5 year survival 21% 8%
5FU Gem HR P value
Median survival 23 mths 23.6 mths 0.94
(0.81-1.08)
P=0.39
5 year survival 21% 8%
N Engl J Med 2004;350(12):1200-10. JAMA 2010;304(10):1073-81.
![Page 7: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/7.jpg)
Toxicity
JAMA 2010;304(10):1073-81.
![Page 8: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/8.jpg)
ESPAC4Gem Cap Gem HR P value
Median survival 28 mths 25.5 mths 0.82
(0.68-0.98)
P=0.032
5 year survival 28.8% 16.3%
Lancet 2017;389:1011-1024.
![Page 9: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/9.jpg)
Optimal duration and timing of adjuvant chemo
J Clin Oncol 2014;32:504-512
• Overall survival favours those who
complete all six cycles of treatment
(HR 0.52; 95% CI (0.44-0.60);
p<0.01)
• No difference in survival if chemo
delayed up to 12 weeks
(HR 0.99; 95% CI (0.95-1.02))
![Page 10: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/10.jpg)
Beyond 12 weeks?
Ann Surg Oncol 2017; 24:2770-2776
![Page 11: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/11.jpg)
NICE guidance
![Page 12: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/12.jpg)
Adjuvant FOLFIRINOXFOLFIRINOX Gem HR P value
Median survival 54.4 mths 35 mths 0.64
(0.48-0.86)
P<0.003
3 year OS 63.4% 48.6%
Conroy T, ASCO 2018
![Page 13: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/13.jpg)
METASTATIC PANCREATIC CANCER
![Page 14: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/14.jpg)
J Clin Oncol 1997;15(6):2403-13
GemcitabineGem 5FU P value
Clinical benefit response 23.8% 4.8% P=0.0022
Median survival 5.65 mths 4.41 mths P=0.025
12 month survival 18% 2%
![Page 15: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/15.jpg)
N Engl J Med 2011;364(19):1817-25
FOLFIRINOXFOLFIRINOX Gem HR P value
Median survival 11.1 mths 6.8 mths 0.57
(0.45-0.73)
P<0.001
![Page 16: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/16.jpg)
N Engl J Med 2011;364(19):1817-25
![Page 17: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/17.jpg)
Toxicity G3/4
N Engl J Med 2011;364(19):1817-25
![Page 18: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/18.jpg)
N Engl J Med 2013; 369(18):1691-703
Gemcitabine/Abraxane
Gem/Abraxane Gem HR P value
Median
survival
8.5 mths 6.7 mths 0.72
(0.62-0.83)
P<0.001
![Page 19: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/19.jpg)
N Engl J Med 2013; 369(18):1691-703
![Page 20: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/20.jpg)
N Engl J Med 2013; 369(18):1691-703
![Page 21: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/21.jpg)
NICE guidance
![Page 22: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/22.jpg)
LOCALLY ADVANCED DISEASE
![Page 23: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/23.jpg)
Chemotherapy
• Response rates combination chemo higher than gemcitabine
alone
• FOLFIRINOX
• Gemcitabine combination
• Gemcitabine
![Page 24: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/24.jpg)
LAP07 Chemo only Chemo +
ChemoRT
HR P value
Median survival 16.5 mths 15.2 mths 1.03
(0.79-1.34)
P=0.83
JAMA 2016;315:1844-1853
![Page 25: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/25.jpg)
Which radiosensitiser?....SCALOP
Lancet Oncol 2013;14:317-326
![Page 26: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/26.jpg)
NICE guidance
![Page 27: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/27.jpg)
DEVELOPING AREAS OF WORK
![Page 28: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/28.jpg)
Downstaging chemotherapy
Early Locally advanced Metastatic
Downstaging
chemotherapy
![Page 29: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/29.jpg)
• Conversion from unresectable or borderline resectable
state to resectable disease
• Increase rate of R0 resections
Downstaging chemotherapy
![Page 30: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/30.jpg)
• Not a new approach!
Downstaging chemotherapy
![Page 31: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/31.jpg)
• All retrospective and prospective studies of neoadjuvant therapy
in patients with pancreatic or periampullary cancers (1980-2009)
• 111 studies (4,394 patients)
Systematic review
PLoS Med 2010; 7(4): e1000267
![Page 32: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/32.jpg)
• All retrospective and prospective studies of neoadjuvant therapy
in patients with pancreatic or periampullary cancers (1980-2009)
• 111 studies (4,394 patients)
• Patients who become resectable after neoadjuvant therapy
have comparable survival to those who were initially
resectable
Systematic review
PLoS Med 2010; 7(4): e1000267
![Page 33: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/33.jpg)
• Improved imaging – high resolution CT/MRI
• Improved surgery – vascular resection
• Improved chemotherapy
Downstaging chemo – a renaissance
![Page 34: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/34.jpg)
Personalised medicine
![Page 35: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/35.jpg)
PRECISION PANC
![Page 36: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/36.jpg)
Immunotherapy…is there a role?
Trends in Cancer 2018;4:418-428
![Page 37: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/37.jpg)
Summary
• Current standard of care treatment informed by evidence base
and endorsed by NICE guidelines.
![Page 38: Oncological Management of Pancreatic Cancer€¦ · Oncological Management of Pancreatic Cancer Pancreatic Cancer UK National Study Day Yuk Ting Ma Senior Clinical Lecturer & Honorary](https://reader033.vdocument.in/reader033/viewer/2022042512/5f5794368e4285600769ca5b/html5/thumbnails/38.jpg)